'About as true as saying the earth is flat': Alzheimer's expert picks apart Biogen's Aduhelm manuscript
Lon Schneider, the University of South California professor who directs the California Alzheimer’s Disease Center, has been one of the most vocal critics of Biogen’s development program for aducanumab. Wary from the beginning, he picked apart the data that Biogen presented along the way and, when the FDA stamped its approval on Aduhelm, was among a group of experts to call for its “accelerated withdrawal” and applauded the CMS’ decision to restrict coverage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.